⚕ GalenOps CRO console
← SITE003 (CAN)

SITE003-0154

completed
Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE003 (CAN) (Dr. Okafor) · consented 2022-09-02
Adverse events
8
Serious AEs
3
Open data queries
0
Luna dropout signal
–

Adverse events

mild assessed 2026-08-18

Grade 1 Pruritus — outcome: RECOVERED/RESOLVED; onset 2022-11-07 (study day 57); relationship: Y

mild assessed 2026-08-18

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-01-20 (study day 131); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-03-31 (study day 201); relationship: not assessed

severe serious assessed 2026-08-18

Grade 4 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-04-23 (study day 224); relationship: N; serious criteria: life-threatening

moderate assessed 2026-08-18

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-10-02 (study day 386); relationship: not assessed

severe serious assessed 2026-08-18

Grade 3 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-11-01 (study day 416); relationship: N; serious criteria: hospitalization

moderate assessed 2026-08-18

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-11-01 (study day 416); relationship: not assessed

severe serious assessed 2026-08-18

Grade 4 Asthenia — outcome: RECOVERED/RESOLVED; onset 2024-03-18 (study day 554); relationship: N; serious criteria: life-threatening

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.